David Heredia, Head of Oncology Department at Punta Médica Hospital, shared on X:
“Press Release. FLAURA2 OS Results
Longer follow-up confirms that osimertinib + chemo offers a statistically significant and clinically meaningful OS benefit over osimertinib alone in 1L EGFRm NSCLC. Reinforces osimertinib as the backbone across stages. Follows the longest-reported PFS in this setting
Looking forward to seeing the full data soon!”
More posts featuring NSCLC.